| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
|
Value Health
|
2007
|
3.93
|
|
2
|
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
|
Value Health
|
2011
|
3.88
|
|
3
|
Systematic review: Effects, design choices, and context of pay-for-performance in health care.
|
BMC Health Serv Res
|
2010
|
2.70
|
|
4
|
Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections.
|
Clin Infect Dis
|
2005
|
2.26
|
|
5
|
Education in pharmacoeconomics: an international multidisciplinary view.
|
Pharmacoeconomics
|
2004
|
2.25
|
|
6
|
A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
|
Intern Med
|
2007
|
2.17
|
|
7
|
Quality of life after intensive care: a systematic review of the literature.
|
Crit Care Med
|
2010
|
1.96
|
|
8
|
Discounting health effects in pharmacoeconomic evaluations: current controversies.
|
Pharmacoeconomics
|
2005
|
1.71
|
|
9
|
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.
|
Diabetes Care
|
2002
|
1.50
|
|
10
|
Health promotion in individuals with mental disorders: a cluster preference randomized controlled trial.
|
BMC Public Health
|
2013
|
1.44
|
|
11
|
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
|
BMC Cancer
|
2013
|
1.43
|
|
12
|
Thinking ahead--the rising tide of AIDS orphans.
|
S Afr Med J
|
2005
|
1.41
|
|
13
|
Economic evaluations in healthcare: comments on a recent article.
|
Reprod Biomed Online
|
2005
|
1.40
|
|
14
|
Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.
|
Int J Antimicrob Agents
|
2008
|
1.11
|
|
15
|
Cost effectiveness of treatments for wet age-related macular degeneration.
|
Pharmacoeconomics
|
2011
|
1.09
|
|
16
|
What reimbursement for coronary revascularization with drug-eluting stents?
|
Eur J Health Econ
|
2004
|
1.09
|
|
17
|
The ties that bind: an integrative framework of physician-hospital alignment.
|
BMC Health Serv Res
|
2011
|
1.08
|
|
18
|
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
|
Value Health
|
2012
|
1.08
|
|
19
|
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.
|
Int J Behav Nutr Phys Act
|
2011
|
1.08
|
|
20
|
Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy.
|
Mov Disord
|
2008
|
1.03
|
|
21
|
The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
|
Pharmacoeconomics
|
2010
|
1.02
|
|
22
|
Health related quality of life in coronary patients and its association with their cardiovascular risk profile: results from the EUROASPIRE III survey.
|
Int J Cardiol
|
2012
|
1.02
|
|
23
|
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
|
Br J Ophthalmol
|
2012
|
1.01
|
|
24
|
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
|
Diabetes Care
|
2004
|
1.00
|
|
25
|
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination.
|
Vaccine
|
2008
|
0.98
|
|
26
|
Psychological well-being and socio-economic hardship among AIDS orphans and other vulnerable children in Guinea.
|
AIDS Care
|
2009
|
0.97
|
|
27
|
Differential pricing of new pharmaceuticals in lower income European countries.
|
Expert Rev Pharmacoecon Outcomes Res
|
2013
|
0.96
|
|
28
|
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
|
Expert Rev Pharmacoecon Outcomes Res
|
2013
|
0.94
|
|
29
|
Reflections on market access for personalized medicine: recommendations for Europe.
|
Value Health
|
2013
|
0.93
|
|
30
|
Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
|
Expert Rev Pharmacoecon Outcomes Res
|
2011
|
0.92
|
|
31
|
Pay-for-performance step-by-step: introduction to the MIMIQ model.
|
Health Policy
|
2010
|
0.91
|
|
32
|
A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
|
Pharmacoeconomics
|
2006
|
0.90
|
|
33
|
EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics.
|
Am Heart J
|
2012
|
0.89
|
|
34
|
The equity dimension in evaluations of the quality and outcomes framework: a systematic review.
|
BMC Health Serv Res
|
2011
|
0.88
|
|
35
|
Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.
|
Value Health
|
2004
|
0.87
|
|
36
|
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
|
Arch Orthop Trauma Surg
|
2004
|
0.87
|
|
37
|
The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.87
|
|
38
|
A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
|
Pharmacoeconomics
|
2006
|
0.86
|
|
39
|
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.
|
Clin Appl Thromb Hemost
|
2010
|
0.86
|
|
40
|
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.
|
Pharmacoeconomics
|
2004
|
0.85
|
|
41
|
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
|
Acta Gastroenterol Belg
|
2007
|
0.85
|
|
42
|
Spinal cord stimulation for predominant low back pain in failed back surgery syndrome: study protocol for an international multicenter randomized controlled trial (PROMISE study).
|
Trials
|
2013
|
0.85
|
|
43
|
Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results.
|
Clin Drug Investig
|
2008
|
0.85
|
|
44
|
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
|
Clin Ther
|
2005
|
0.85
|
|
45
|
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
|
Pharmacoeconomics
|
2010
|
0.84
|
|
46
|
Economic burden of pertussis and the impact of immunization.
|
Pediatr Infect Dis J
|
2005
|
0.84
|
|
47
|
Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
|
J Eval Clin Pract
|
2014
|
0.83
|
|
48
|
The impact of economic and noneconomic exchange on physicians' organizational attitudes: The moderating effects of the Chief Medical Officer.
|
Health Care Manage Rev
|
2015
|
0.83
|
|
49
|
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
|
Eur Heart J
|
2012
|
0.83
|
|
50
|
Hospital-physician relations: the relative importance of economic, relational and professional attributes to organizational attractiveness.
|
BMC Health Serv Res
|
2014
|
0.82
|
|
51
|
Economic evaluation of different treatment modalities in acute kidney injury.
|
Nephrol Dial Transplant
|
2012
|
0.82
|
|
52
|
A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany.
|
Expert Rev Pharmacoecon Outcomes Res
|
2012
|
0.81
|
|
53
|
Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
|
CNS Drugs
|
2008
|
0.81
|
|
54
|
A cost-effectiveness study of the community-based intervention '10 000 Steps Ghent'.
|
Public Health Nutr
|
2011
|
0.81
|
|
55
|
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
|
Nephrol Dial Transplant
|
2003
|
0.81
|
|
56
|
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
|
J Med Econ
|
2013
|
0.81
|
|
57
|
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
|
Kidney Int Suppl
|
2005
|
0.81
|
|
58
|
Projected reduction in healthcare costs in Belgium after optimization of iodine intake: impact on costs related to thyroid nodular disease.
|
Thyroid
|
2010
|
0.81
|
|
59
|
Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).
|
Pharmacoeconomics
|
2014
|
0.81
|
|
60
|
Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
|
J Hosp Med
|
2011
|
0.81
|
|
61
|
An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
|
Eur J Prev Cardiol
|
2011
|
0.80
|
|
62
|
Nurse-led telecoaching of people with type 2 diabetes in primary care: rationale, design and baseline data of a randomized controlled trial.
|
BMC Fam Pract
|
2014
|
0.80
|
|
63
|
Medical homes versus individual practice in primary care: impact on health care expenditures.
|
Med Care
|
2013
|
0.80
|
|
64
|
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
|
Clin Ther
|
2003
|
0.80
|
|
65
|
Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
|
Trop Med Int Health
|
2010
|
0.80
|
|
66
|
Cost-effectiveness of a helpline for suicide prevention.
|
J Telemed Telecare
|
2013
|
0.80
|
|
67
|
A critical literature review of health economic evaluations in pertussis booster vaccination.
|
Expert Rev Pharmacoecon Outcomes Res
|
2012
|
0.80
|
|
68
|
European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
|
Cancer Treat Rev
|
2006
|
0.80
|
|
69
|
Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms.
|
Am J Cardiovasc Drugs
|
2012
|
0.79
|
|
70
|
Medication use and disease management of type 2 diabetes in Belgium.
|
Pharm World Sci
|
2007
|
0.79
|
|
71
|
Impact of the medical home model on the quality of primary care: the Belgian experience.
|
Med Care
|
2015
|
0.79
|
|
72
|
Health promotion intervention in mental health care: design and baseline findings of a cluster preference randomized controlled trial.
|
BMC Public Health
|
2012
|
0.78
|
|
73
|
Health promotion in mental health care: perceptions from patients and mental health nurses.
|
J Clin Nurs
|
2013
|
0.78
|
|
74
|
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
|
Pharmacoeconomics
|
2010
|
0.78
|
|
75
|
A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions.
|
Pharmacoeconomics
|
2014
|
0.78
|
|
76
|
Healthcare payment reforms across western countries on three continents: lessons from stakeholder preferences when asked to rate the supportiveness for fulfilling patients' needs.
|
Health Policy
|
2013
|
0.78
|
|
77
|
Gonadotropin Therapy versus Laparoscopic Ovarian Drilling in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome Patients: A Retrospective Cost-Effectiveness Analysis.
|
Gynecol Obstet Invest
|
2015
|
0.78
|
|
78
|
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
|
J Med Econ
|
2013
|
0.78
|
|
79
|
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
|
Clin Drug Investig
|
2015
|
0.77
|
|
80
|
Cost-effectiveness of health promotion targeting physical activity and healthy eating in mental health care.
|
BMC Public Health
|
2014
|
0.77
|
|
81
|
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
|
Curr Med Res Opin
|
2006
|
0.77
|
|
82
|
Risk factor awareness in a coronary population and the association with health-related quality of life outcomes.
|
Int J Public Health
|
2014
|
0.77
|
|
83
|
Attitudes toward supplementary criteria in the reimbursement process in Poland.
|
Int J Technol Assess Health Care
|
2013
|
0.77
|
|
84
|
Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.
|
Expert Rev Pharmacoecon Outcomes Res
|
2012
|
0.76
|
|
85
|
Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.
|
PLoS One
|
2013
|
0.76
|
|
86
|
Stimulating pharmaceutical innovation in the EU.
|
Expert Rev Pharmacoecon Outcomes Res
|
2011
|
0.76
|
|
87
|
A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
|
Herz
|
2006
|
0.76
|
|
88
|
Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram.
|
Int J Psychiatry Clin Pract
|
2007
|
0.76
|
|
89
|
Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
|
Oncologist
|
2008
|
0.76
|
|
90
|
Comment on "Health-related quality of life as a prognostic factor of survival in critically ill patients".
|
Intensive Care Med
|
2009
|
0.75
|
|
91
|
Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
|
Pharmacoeconomics
|
2015
|
0.75
|
|
92
|
Estimating the length of hospitalization attributable to multidrug antibiotic resistance.
|
Antimicrob Agents Chemother
|
2010
|
0.75
|
|
93
|
Hospital costs in patients with nosocomial methicillin-resistant or methicillin-susceptible Staphylococcus aureus bloodstream infection.
|
Infect Control Hosp Epidemiol
|
2009
|
0.75
|
|
94
|
Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.
|
Expert Rev Pharmacoecon Outcomes Res
|
2007
|
0.75
|
|
95
|
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients.
|
Clinicoecon Outcomes Res
|
2012
|
0.75
|
|
96
|
A health economic evaluation of concomitant surgical ablation for atrial fibrillation.
|
Eur J Cardiothorac Surg
|
2007
|
0.75
|
|
97
|
Stratified medicine: a call for action.
|
Expert Rev Pharmacoecon Outcomes Res
|
2013
|
0.75
|
|
98
|
Networks for improving care in patients with acute coronary syndrome: A framework.
|
Acute Card Care
|
2014
|
0.75
|
|
99
|
Hurdles that impede economic evaluations of welfare interventions.
|
Expert Rev Pharmacoecon Outcomes Res
|
2015
|
0.75
|
|
100
|
Inventory of European databases related to cardiovascular diseases.
|
Eur Heart J
|
2012
|
0.75
|
|
101
|
Health economic evaluation of liver MRI in colorectal cancer patients.
|
Eur Radiol
|
2004
|
0.75
|
|
102
|
How to improve screening in first-degree relatives of patients with premature coronary heart disease.
|
Eur J Cardiovasc Prev Rehabil
|
2006
|
0.75
|
|
103
|
Critical appraisal of scientific posters comparing anemia treatments for cancer patients: applying ISPOR Task Force guidelines on methodological quality of retrospective studies.
|
Crit Rev Oncol Hematol
|
2007
|
0.75
|
|
104
|
Critically ill octogenarians and nonagenarians: evaluation of long-term outcomes, post-hospital trajectories and quality of life one year and seven years after ICU discharge.
|
Minerva Anestesiol
|
2016
|
0.75
|
|
105
|
Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
|
Expert Rev Vaccines
|
2010
|
0.75
|
|
106
|
506: DEVELOPMENT OF A PREDICTION MODEL FOR LONG-TERM QUALITY OF LIFE IN CRITICALLY ILL PATIENTS.
|
Crit Care Med
|
2016
|
0.75
|
|
107
|
Comparative effectiveness: beyond the buzz.
|
J Med Econ
|
2012
|
0.75
|
|
108
|
Progress in vaccines, progress in health economics.
|
Vaccine
|
2010
|
0.75
|
|
109
|
Proteinuria and clinical outcomes in hypertensive patients.
|
Am J Hypertens
|
2009
|
0.75
|
|
110
|
[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
|
Bull Cancer
|
2008
|
0.75
|
|
111
|
505: LONGITUDINAL PREDICTION MODEL FOR LONG-TERM QUALITY OF LIFE IN CRITICALLY ILL PATIENTS.
|
Crit Care Med
|
2016
|
0.75
|
|
112
|
The cost of alcohol in the workplace in Belgium.
|
Psychiatr Danub
|
2013
|
0.75
|
|
113
|
Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.
|
Expert Opin Pharmacother
|
2006
|
0.75
|
|
114
|
Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.
|
J Med Econ
|
2012
|
0.75
|
|
115
|
[Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
|
Rev Esp Cardiol
|
2006
|
0.75
|